看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。! R/ Z8 O3 x/ Y; l# A/ A' j
$ V; J* X$ c" I/ s, Z; V) `! s9 P
, ?$ t2 |2 g4 h9 S# V" VCurrently available feasibility data for possible combination strategies.
2 B2 C6 u7 b& J4 {& c————————————————————————————————; @$ o* B" C( G$ {2 E
Combination Feasibility according to preliminary data
% ^3 j0 W6 \9 P4 s" T——————————————————————————————————/ F# _1 F, d% k* f/ Q' l( s
Bevacizumab + sorafenib Yes, reduced dose
8 K+ d2 U' n$ T" z( T7 tBevacizumab + sunitinib† No
}" [0 J9 m" k- gBevacizumab + temsirolimus Yes 5 M. ]; w+ @& l, H
Bevacizumab + everolimus Yes 6 ^! `# k+ e) r% N; y/ D s3 W
Sorafenib + sunitinib ?
3 \ s% ^; d6 U* LSorafenib + temsirolimus Yes, reduced dose
) v3 T5 ?0 E6 |; RSorafenib + everolimus Yes, reduced dose 5 \ G5 e$ Q' g! I2 `
Sunitinib + temsirolimus† No ; o; D' G7 [0 }) g
Sunitinib + everolimus ? # q9 o x4 x- S5 k
Temsirolimus + everolimus ?
5 T3 R' r5 a H————————————————————
7 t) g6 X# y4 L# G) M. ~†Led to US FDA warning.
" ]2 ^5 p$ r" J3 B- `& ??: As yet unattempted combination.5 k2 u0 [% T5 f6 Z
|
显身卡
5 X( \+ ^: k3 ^5 K: p
